These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 35106717)

  • 1. Low-dosage ethambutol, less than 12.5 mg/kg/day, does not worsen the clinical outcomes of pulmonary Mycobacterium avium and Mycobacterium intracellulare disease: a retrospective cohort study.
    Watanabe F; Kaburaki S; Furuuchi K; Uesugi F; Fujiwara K; Tanaka Y; Yoshiyama T; Shiraishi Y; Kurashima A; Ohta K; Hanada K; Morimoto K
    Infection; 2022 Aug; 50(4):879-887. PubMed ID: 35106717
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of ethambutol and rifampicin in the treatment of Mycobacterium avium complex pulmonary disease.
    Kim HJ; Lee JS; Kwak N; Cho J; Lee CH; Han SK; Yim JJ
    BMC Pulm Med; 2019 Nov; 19(1):212. PubMed ID: 31711459
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lower dose of ethambutol may reduce ocular toxicity without radiological deterioration for Mycobacterium avium complex pulmonary disease.
    Ando T; Kage H; Matsumoto Y; Zokumasu K; Nagase T
    Respir Investig; 2021 Nov; 59(6):777-782. PubMed ID: 34389250
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of clarithromycin and ethambutol for Mycobacterium avium complex pulmonary disease. A preliminary study.
    Miwa S; Shirai M; Toyoshima M; Shirai T; Yasuda K; Yokomura K; Yamada T; Masuda M; Inui N; Chida K; Suda T; Hayakawa H
    Ann Am Thorac Soc; 2014 Jan; 11(1):23-9. PubMed ID: 24298907
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intermittent antibiotic therapy for nodular bronchiectatic Mycobacterium avium complex lung disease.
    Jeong BH; Jeon K; Park HY; Kim SY; Lee KS; Huh HJ; Ki CS; Lee NY; Shin SJ; Daley CL; Koh WJ
    Am J Respir Crit Care Med; 2015 Jan; 191(1):96-103. PubMed ID: 25393520
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and Efficacy of Clofazimine as an Alternative for Rifampicin in Mycobacterium avium Complex Pulmonary Disease Treatment: Outcomes of a Randomized Trial.
    Zweijpfenning SMH; Aarnoutse R; Boeree MJ; Magis-Escurra C; Stemkens R; Geurts B; van Ingen J; Hoefsloot W
    Chest; 2024 May; 165(5):1082-1092. PubMed ID: 38040054
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intermittent Treatment with Azithromycin and Ethambutol for Noncavitary Mycobacterium avium Complex Pulmonary Disease.
    Moon SM; Yoo IY; Huh HJ; Lee NY; Jhun BW
    Antimicrob Agents Chemother; 2019 Dec; 64(1):. PubMed ID: 31611366
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effective treatment for clarithromycin-resistant Mycobacterium avium complex lung disease.
    Adachi Y; Tsuyuguchi K; Kobayashi T; Kurahara Y; Yoshida S; Kagawa T; Hayashi S; Suzuki K
    J Infect Chemother; 2020 Jul; 26(7):676-680. PubMed ID: 32171660
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relationship between Resistance to Ethambutol and Rifampin and Clinical Outcomes in Mycobacterium avium Complex Pulmonary Disease.
    Moon SM; Kim SY; Kim DH; Huh HJ; Lee NY; Jhun BW
    Antimicrob Agents Chemother; 2022 Apr; 66(4):e0202721. PubMed ID: 35266825
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term Follow-up of Mycobacterium avium Complex Lung Disease in Patients Treated With Regimens Including Clofazimine and/or Rifampin.
    Jarand J; Davis JP; Cowie RL; Field SK; Fisher DA
    Chest; 2016 May; 149(5):1285-93. PubMed ID: 26513209
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of treatment outcomes between intermittent and daily regimens in non-cavitary nodular bronchiectatic-type
    Jung J; Chong YP; Lee HJ; Shim TS; Jo K-W
    Antimicrob Agents Chemother; 2023 Nov; 67(11):e0100323. PubMed ID: 37843254
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tolerability Outcomes of American Thoracic Society/Infectious Diseases Society of America Guideline-Recommended Multidrug Antibiotic Treatment for Mycobacterium avium Complex Pulmonary Disease in US Medicare Beneficiaries With Bronchiectasis.
    Ku JH; Henkle E; Carlson KF; Marino M; Brode SK; Marras TK; Winthrop KL
    Chest; 2024 May; 165(5):1058-1069. PubMed ID: 38086472
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A comparison of two regimens for the treatment of Mycobacterium avium complex bacteremia in AIDS: rifabutin, ethambutol, and clarithromycin versus rifampin, ethambutol, clofazimine, and ciprofloxacin. Canadian HIV Trials Network Protocol 010 Study Group.
    Shafran SD; Singer J; Zarowny DP; Phillips P; Salit I; Walmsley SL; Fong IW; Gill MJ; Rachlis AR; Lalonde RG; Fanning MM; Tsoukas CM
    N Engl J Med; 1996 Aug; 335(6):377-83. PubMed ID: 8676931
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of Fluoroquinolones as Substitutes for Ethambutol or Rifampin in the Treatment of Mycobacterium avium Complex Pulmonary Disease According to Radiologic Types.
    Lee JH; Park YE; Chong YP; Shim TS; Jo KW
    Antimicrob Agents Chemother; 2022 Feb; 66(2):e0152221. PubMed ID: 34930036
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The clinical efficacy of a clarithromycin-based regimen for Mycobacterium avium complex disease: A nationwide post-marketing study.
    Kadota JI; Kurashima A; Suzuki K
    J Infect Chemother; 2017 May; 23(5):293-300. PubMed ID: 28254517
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of combined therapy according to the guidelines for the treatment of Mycobacterium avium complex pulmonary disease.
    Kobashi Y; Matsushima T
    Intern Med; 2003 Aug; 42(8):670-5. PubMed ID: 12924489
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The influence of environmental exposure on the response to antimicrobial treatment in pulmonary Mycobacterial avium complex disease.
    Ito Y; Hirai T; Fujita K; Kubo T; Maekawa K; Ichiyama S; Togashi K; Mishima M
    BMC Infect Dis; 2014 Sep; 14():522. PubMed ID: 25266993
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment outcomes and relapse in patients with
    Chang CL; Yu CJ; Hsueh PR; Chien JY
    Microbiol Spectr; 2023 Sep; 11(5):e0164023. PubMed ID: 37754771
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multicentre, open label, randomised controlled trial comparing intermittent versus daily treatment for non-cavitary nodular/bronchiectatic
    Nakagawa T; Hashimoto H; Yagi M; Kogure Y; Sekimizu M; Saito AM; Ogawa K; Inoue Y
    BMJ Open Respir Res; 2019; 6(1):e000434. PubMed ID: 31258920
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Macrolide resistant Mycobacterium avium complex pulmonary disease following clarithromycin and ethambutol combination therapy.
    Ito Y; Miwa S; Shirai M; Kanai M; Fujita K; Ohba H; Iwaizumi E; Oshima T; Kojima S; Suda T; Hayakawa H
    Respir Med; 2020 Aug; 169():106025. PubMed ID: 32442113
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.